Catalog No.: PC-20215Not For Human Use, Lab Use Only.
Vamotinib (PF-114) is a potent, selective and orally available inhibitor of native (IC50=0.49 nM) and mutated BCR/ABL (IC50=0.7-4 nM, ABL (T315I) IC50=0.78 nM).
Vamotinib (PF-114) is a potent, selective and orally available inhibitor of native (IC50=0.49 nM) and mutated BCR/ABL (IC50=0.7-4 nM, ABL (T315I) IC50=0.78 nM).
PF-114 potently inhibits ABL2, DDR1, DDR2, FMS, FRK, LCK, LYN and PDGFR kinases, but did not inhibit c-SRC, CSK, or c-KIT.
PF-114 is a potent TKI with a more restricted selectivity profile as compared to ponatinib or dasatinib.
PF-114 inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I and abolishes factor-independent growth of Ba/F3 cells mediated by BCR/ABL and its resistance mutants.
PF-114 potently inhibits Ph+ patient derived cell lines, abolishes tumor growth in a K562 nude-mouse xenograft model.
PF-114 suppresses growth of Ph+ PD-LTC with non mutational resistance as well as T315I mutation.
PF-114 prolongs the survival of mice with both BCR/ABL- and BCR/ABL-T315I-driven CMLlike disease.
